Guanosine 5'-O-2-thiodiphosphate trisodium

Guanosine 5'-O-(2-thiodiphosphate) (1 µM) blocks norepinephrine-induced nitric oxide release in adult rat ventricular myocytes^[1].
Guanosine 5'-O-(2-thiodiphosphate) acts as a partial agonist for adenylate cyclase activation in synaptic membranes of the rat cerebral cortex, with an EC₅₀ of 4×10^-7 M and a maximum activation level equivalent to 60% of that of the GTP triphosphate analog^[2].
Guanosine 5'-O-(2-thiodiphosphate) (1 μM) enhances adenylate cyclase activation mediated by low-dose GTPγS (HY-137677), while inhibiting activation induced by high-dose GTPγS in synaptic membranes from rat cerebral cortex^[2].
Guanosine 5'-O-(2-thiodiphosphate) promotes partial nucleotide exchange from G_i/o to G_s (EC₅₀ = 2×10^-5 M) and partially reverses the inhibitory effect of adenylate cyclase (EC₅₀ = 5×10^-6 M). Its potency and efficacy in rat cerebral cortical synaptic membranes are both lower than those of GppNHp^[2].
Guanosine 5'-O-(2-thiodiphosphate) competitively inhibits GTP-stimulated adenylate cyclase activity in cholera toxin-pretreated rat pancreatic plasma membranes, with a K_i range of 0.3-0.6 μM^[3].
Guanosine 5'-O-(2-thiodiphosphate) inhibits cholecystokinin-8 (CCK-8)-stimulated adenylate cyclase activity in native rat pancreatic plasma membranes; in the presence of 0.3 μM GTP, its I₅₀ is 2.2 μM and K_i is 0.5 μM^[3].
Guanosine 5'-O-(2-thiodiphosphate) inhibits secretin+GTP-stimulated adenylate cyclase activity in native rat pancreatic plasma membranes, with an IC₅₀ of 8 μM and a K_i of 3.2 μM^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.